Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 691 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
13 Results
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
- Lung Cancer
Peripheral Blood Profiling to Screen Patients for Lung Cancer or Lung Cancer Recurrence
- Lung Cancer
- Respiratory System
The Cancer of the Pancreas Screening-5 (CAPS5) Study
- Pancreatic Cancer
- Gender:All Genders
- Age:18 years and older
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
- Leukemia & Hematologic Cancers
A Single Arm Phase II Trial of Circulating Tumor DNA-guided Adjuvant Therapy With Elacestrant in Hormone Receptor Positive HER2 Negative Breast Cancers at Risk for Late Recurrence (CATE)
- Breast Cancer
First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors
- Phase 1 Cancers
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Sarcoma Cancers
- Brain & Other Nervous System Cancers
- Eye Cancers
- Lymphoma
- Kidney Cancer
- Leukemia & Hematologic Cancers
- Liver Cancer
- Gastrointestinal Cancers
- Thyroid & Other Endocrine Cancers
- Gynecological Cancers
- Male Genital Cancers
- Lung Cancer
- Skin Cancers & Melanoma
- Bladder Cancer
- Colorectal Cancer
- Pediatric Cancers
A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors
- Breast Cancer
An Interventional Phase 1b/2, Open-Label Study to Investigate the Safety, Antitumor Activity, and Pharmacokinetics of PF-08634404 Monotherapy or in Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer
- Bladder Cancer
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Phase 1 Cancers
1-10 of 13 Results